Current topics in CAR T-cell therapy

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

Nov 2024
Duration 18 mins 28 secs

During this discussion, Canadian CAR T experts review pivotal trial and current real-world evidence supporting use of CAR T cell for patients with large B-cell lymphoma (LBCL), with a focus on treatment in the second-line (2L) setting. Experts also discuss key clinical and practical considerations for all stages of the 2L CAR T journey, including synergies between referral and treatment centres.

Click here to evaluate this content

Watch
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma – Part 1

May 2025
Duration 7 mins 46 secs

These are recordings of Kite’s symposium at CTTC 2025 entitled “From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma.” In part 1, Dr. Balitsky introduces the session and discusses the evolving role of CAR T cell therapy in 2L for R/R LBCL. In Part 2, Dr. Lemieux presents a series of patient cases to highlight the role of CAR T in diverse patient populations. In part 3, through a patient case, Dr. Shafey shares best practices for managing rapidly progressing DLBCL and discusses strategies for CAR T capacity planning.  

Click here to evaluate this content

Watch
From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma – Part 1

The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience – Part 1

Oct 2025
Duration 14 mins 35 secs

These are recordings of Kite’s symposium at CANO 2025 entitled “The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience.” In part 1, Nurse Practitioner, Linda Hamelin provides an overview of the current CAR T journey and 2L LBCL treatment landscape in Canada. In part 2, a panel discussion led by RN Josh Smith walks through a patient case with scenario-based modifications, highlighting the critical role of nurses prior to CAR T treatment. RN Julie Campeau also shares insights on the referral process for CAR T. In part 3, a panel discussion led by RN Melissa Vicencio discusses the critical role of nurses during CAR T infusion and post-infusion. The symposium concludes with a panel discussion where nurses share insights and experiences with the evolving CAR T models at their respective Canadian centers.

Click here to evaluate this content

Watch
The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience – Part 1

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 1

Jun 2026
Duration 28 mins 58 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 1, Dr. Puckrin provides an overview of the TRIANGLE and ECHO protocols to integrate BTKi use into frontline therapy. He highlights considerations for high-risk patients, impacts on treatment sequencing, and considerations for patient preferences.

Click here to evaluate this content

Watch
Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 1

Webinars & Tutorials

Visit page
Expert Discussion on CAR T Therapy for Relapsed and Refractory Mantle Cell Lymphoma

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada - Part 1

Jun 2026
Duration 28 mins 58 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 1, Dr. Puckrin provides an overview of the TRIANGLE and ECHO protocols to integrate BTKi use into frontline therapy. He highlights considerations for high-risk patients, impacts on treatment sequencing, and considerations for patient preferences.

View
Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 2

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 2

Jun 2026
Duration 17 mins 6 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 2, Dr. Puckrin has a pragmatic discussion for approaches to choosing BTKi-containing regimens and CAR T-cell therapy in an era where BTKi use is moving up in treatment sequence.

View
Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 3

Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Part 3

Jun 2026
Duration 6 mins 11 secs

This is a presentation titled “Evolving Treatment Landscape for Mantle Cell Lymphoma in Canada”. In part 3, Dr. Puckrin highlights emerging T-cell engaging therapies and non-covalent BTKi treatments in R/R MCL.

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 1: Practical Approaches to Delivering CAR T-Cell Therapy in 2L LBCL

Nov 2024
Duration 18 mins 28 secs

During this discussion, Canadian CAR T experts review pivotal trial and current real-world evidence supporting use of CAR T cell for patients with large B-cell lymphoma (LBCL), with a focus on treatment in the second-line (2L) setting. Experts also discuss key clinical and practical considerations for all stages of the 2L CAR T journey, including synergies between referral and treatment centres.

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 2: 2L CAR T for Primary Refractory LBCL

Nov 2024
Duration 13 mins 13 secs

In this video, Canadian CAR T experts review a clinical case of primary refractory LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary refractory LBCL, including patient eligibility and preparation.

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 3: 2L CART for Primary Progressive LBCL

Nov 2024
Duration 16 mins 3 secs

In this video, Canadian CAR T experts review a clinical case of primary progressive LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with primary progressive LBCL, including the role of holding/bridging therapy and the importance of quick communication between referral and treatment centres.

View
CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

CAR T Cell Therapy for Refractory and Early Relapsed DLBCL - Part 4: 2L CART for early relapsed (<12 months) LBCL

Nov 2024
Duration 17 mins 34 secs

In this video, Canadian CAR T experts review a clinical case of early relapsed (<12 months) LBCL. During this discussion, the experts review key clinical and logistical aspects for all stages of the 2L CAR T journey for patients with early relapsed (<12 months) LBCL, including the importance of re-biopsy and of referral and treatment centres partnership.

View

Congress Symposia

Visit page
Age is Not a Barrier: The Older Patient with Comorbidities

Age is Not a Barrier: The Older Patient with Comorbidities

Jun 2024
Duration 20 mins 41 secs

This is a recording from a segment of Kite’s global symposium at EHA 2025 titled “Doctor, what is my best chance of a cure? A case-based approach to the evolving landscape of R/R lymphomas.” In this portion of the symposium, Dr. Anderson presents a case study and uses real-world evidence to discuss the current best-practices and role of CAR T in elderly patients with co-morbidities.

View
Improving Survival Outcomes: Incorporating CAR T Therapy Earlier into a Patient’s Journey with Aggressive Lymphoma - Part 1

From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma – Part 1

May 2025
Duration 7 mins 46 secs

These are recordings of Kite’s symposium at CTTC 2025 entitled “From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma.” In part 1, Dr. Balitsky introduces the session and discusses the evolving role of CAR T cell therapy in 2L for R/R LBCL. In Part 2, Dr. Lemieux presents a series of patient cases to highlight the role of CAR T in diverse patient populations. In part 3, through a patient case, Dr. Shafey shares best practices for managing rapidly progressing DLBCL and discusses strategies for CAR T capacity planning.

View
Improving Survival Outcomes: Incorporating CAR T Therapy Earlier into a Patient’s Journey with Aggressive Lymphoma - Part 2

From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma – Part 2

May 2025
Duration 28 mins 59 secs

These are recordings of Kite’s symposium at CTTC 2025 entitled “From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma.” In part 1, Dr. Balitsky introduces the session and discusses the evolving role of CAR T cell therapy in 2L for R/R LBCL. In Part 2, Dr. Lemieux presents a series of patient cases to highlight the role of CAR T in diverse patient populations. In part 3, through a patient case, Dr. Shafey shares best practices for managing rapidly progressing DLBCL and discusses strategies for CAR T capacity planning.

View
From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma – Part 3

From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma – Part 3

May 2025
Duration 15 mins 03 secs

These are recordings of Kite’s symposia at CTTC 2025 entitled “From Promise to Practice: Case-Based Discussion on Standard of Care Second-line (2L) CAR T Therapy for Aggressive Lymphoma.” In part 1, Dr. Balitsky introduces the session and discusses the evolving role of CAR T cell therapy in 2L for R/R LBCL. In Part 2, Dr. Lemieux presents a series of patient cases to highlight the role of CAR T in diverse patient populations. In part 3, through a patient case, Dr. Shafey shares best practices for managing rapidly progressing DLBCL and discusses strategies for CAR T capacity planning.

View
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 1

The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience – Part 1

Oct 2025
Duration 14 mins 35 secs

These are recordings of Kite’s symposium at CANO 2025 entitled “The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience.” In part 1, Nurse Practitioner, Linda Hamelin provides an overview of the current CAR T journey and 2L LBCL treatment landscape in Canada. In part 2, a panel discussion led by RN Josh Smith walks through a patient case with scenario-based modifications, highlighting the critical role of nurses prior to CAR T treatment. RN Julie Campeau also shares insights on the referral process for CAR T. In part 3, a panel discussion led by RN Melissa Vicencio discusses the critical role of nurses during CAR T infusion and post-infusion. The symposium concludes with a panel discussion where nurses share insights and experiences with the evolving CAR T models at their respective Canadian centers.

View
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 2

The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience – Part 2

Oct 2025
Duration 8 mins 06 secs

These are recordings of Kite’s symposium at CANO 2025 entitled “The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience.” In part 1, Nurse Practitioner, Linda Hamelin provides an overview of the current CAR T journey and 2L LBCL treatment landscape in Canada. In part 2, a panel discussion led by RN Josh Smith walks through a patient case with scenario-based modifications, highlighting the critical role of nurses prior to CAR T treatment. RN Julie Campeau also shares insights on the referral process for CAR T. In part 3, a panel discussion led by RN Melissa Vicencio discusses the critical role of nurses during CAR T infusion and post-infusion. The symposium concludes with a panel discussion where nurses share insights and experiences with the evolving CAR T models at their respective Canadian centers.

View
The Role of Nurses in a Patient’s Path to CAR T Therapy and Post Treatment Care with Aggressive Lymphoma - Part 3

The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience – Part 3

Oct 2025
Duration 29 mins 11 secs

These are recordings of Kite’s symposium at CANO 2025 entitled “The Evolving CAR T Journey for Patients with Aggressive Lymphoma and the Critical Role of Nurses—A Canadian Experience.” In part 1, Nurse Practitioner, Linda Hamelin provides an overview of the current CAR T journey and 2L LBCL treatment landscape in Canada. In part 2, a panel discussion led by RN Josh Smith walks through a patient case with scenario-based modifications, highlighting the critical role of nurses prior to CAR T treatment. RN Julie Campeau also shares insights on the referral process for CAR T. In part 3, a panel discussion led by RN Melissa Vicencio discusses the critical role of nurses during CAR T infusion and post-infusion. The symposium concludes with a panel discussion where nurses share insights and experiences with the evolving CAR T models at their respective Canadian centers.

View
Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Understanding the Role of CAR T in R/R Adult ALL and Exploring CAR T Treatment Approaches in R/R Adult ALL

Jun 2023
Duration 27 mins 21 secs

As part of Kite’s symposia at EHA 2023 entitled “Managing R/R Adult ALL in the CAR T Era”, Dr. Shah and Dr. Rabian discuss CAR T treatment approaches in R/R adult ALL, including clinical trial and real-world data updates, as well as present real patient cases.

View